RecruitingPhase 2NCT06969534
Safety and Efficacy of Pucotenlimab in pLECC
Studying Lymphoepithelial-like carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sun Yat-sen University
- Intervention
- Pucotenlimab combined with GP regimen(drug)
- Enrollment
- 33 target
- Eligibility
- 1-18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (1)
- Yizhuo Zhang, Guangzhou, Guangdong, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06969534 on ClinicalTrials.govOther trials for Lymphoepithelial-like carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06568172Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin CancerNational Cancer Institute (NCI)
- RECRUITINGNCT06801977The Chinese Pulmonary Lymphoepithelioma-like Carcinoma Collaboration StudySun Yat-sen University